Lifestyle

Health & Fitness

Fitness, nutrition, recovery, sleep, mental wellness, and living better

Stories
200
stories
Sources
7
sources
Page
Page 8 of 10
Updated hourly

Why Owl Post covers Health & Fitness

Health and fitness coverage is dominated by fad protocols, supplement marketing dressed as research, and wellness influencers who swap their recommendations when the sponsorship changes.

The durable signal in this space is boring by comparison: strength training keeps appearing in longevity research, consistent sleep keeps outperforming sleep hacks, walking keeps showing up as underrated. Owl Post reads the actual research behind these claims, evaluates how solid the study design is, and surfaces what is holding up across independent replications versus what is one viral study away from being overturned.

Read the full Health & Fitness briefing

The beat covers exercise science (strength, cardio, mobility, and the research on optimal protocols), nutrition (what the evidence actually shows about diet patterns, not whatever is trending), sleep and recovery, mental health and its intersection with physical practice, and the broader wellness industry, including how to evaluate claims critically. Owl Post reads peer-reviewed research, follows the scientists and physicians doing serious work, and reads the publications that hold their reporting to an evidence standard.

Your digest adapts to how you engage with health information. If you want the science explained at the mechanism level, with the study quality assessed, that framing is available. If you want the practical implementation angle, focused on what to actually change based on the evidence, that works too. Either way, the sourcing is from people and institutions that cite their work.

A daily health and fitness digest. What the research actually shows, applied to how you actually live. The goal is not more information about wellness. It is better information, filtered by people who read the studies and know how to evaluate them.

GLP-1s Like Ozempic, Mounjaro Linked to Reduced Stroke, Heart Risks

A growing body of evidence shows that GLP-1 drugs benefit cardiovascular health. Image Credit: Healthline/Munro/Getty Images GLP-1 medications like Ozempic and Wegovy help protect heart health, but stopping the medications may reduce the protective effects. Some research suggests that GLP-1s containing tirzepatide (Zepbound, Mounjaro) may help lower the risk of further complications in people with cardiovascular disease. Other research suggests that GLP-1s may help reduce thromboembolic events, such as deep vein thrombosis (DVT), in people with obesity and autoimmune diseases. GLP-1 medications were originally developed for the management of type 2 diabetes. Now, GLP-1 medications, such as Ozempic, Wegovy, and Mounjaro, are widely prescribed for weight management in people with overweight or obesity. A large body of evidence shows that GLP-1s offer health benefits beyond diabetes and weight loss. Recent research published in BMJ Medicine suggests that GLP-1 medications may support heart health, with cardiovascular benefits increasing with longer duration of use. However, stopping the medication may reduce heart-protective benefits. Findings presented at the SCAI 2026 Scientific Sessions & CAIC-ACCI Summit in Montreal in April indicate that GLP-1 medications containing tirzepatide (Mounjaro and Zepbound) may help lower the risk of heart problems in people with obesity undergoing certain heart procedures. A research article in the Journal of the American Heart Association (JAHA) explored additional benefits of GLP-1 drugs, with some findings suggesting a reduced risk of thromboembolic events, such as DVT and pulmonary embolism. Tirzepatide GLP-1s lower risk of heart procedure complications Two studies on the potential benefits of the GLP-1 receptor agonist tirzepatide were presented at the SCAI 2026 Scientific Sessions & CAIC-ACCI Summit in Montreal in April. The studies have not yet been published in a peer-reviewed scientific journal, but a news release detailed som

healthline.com
FDA Approves ‘New’ Sunscreen Ingredient Used in Europe and Asia for Years

FDA Approves ‘New’ Sunscreen Ingredient Used in Europe and Asia for Years

Bemotrizinol (PARSOL Shield), an advanced sunscreen filter that has long been used in Europe and Asia, has been approved for use in the U.S. by the FDA. Image Credit: has approved bemotrizinol (PARSOL Shield). This is the first new sunscreen ingredient approved in over 20 years, offering superior UVA and UVB protection. Consumers in the United States can expect new products featuring PARSOL Shield by the end of 2026, with broader availability to follow. This innovation closes the UVA protection gap and paves the way for more effective, cosmetically elegant sunscreens. The Food and Drug Administration (FDA) has approved bemotrizinol (PARSOL Shield), an advanced sunscreen filter that has long been used in Europe and Asia. It is the first new sunscreen ingredient approved by the FDA in over 20 years and will offer consumers improved UVA protection. It will also pave the way for a new generation of sunscreens. “Bemotrizinol has been used safely in Europe for decades, and [the] FDA’s action will increase competition and consumer confidence in sunscreen products,” HHS Secretary Robert F. Kennedy, Jr said in a press release. Bemotrizinol (PARSOL Shield) is a chemical sunscreen filter that is recognized for its broad-spectrum UVA and UVB protection. It is photostable and effective at concentrations up to 6%. Unlike many older filters, bemotrizinol is absorbed minimally through the skin, with plasma levels rarely exceeding FDA thresholds. “This is exactly the kind of progress we can achieve when we modernize our processes and apply sound science to regulatory decisions,” Mike Davis, MD, Acting Director of the FDA Center for Drug Evaluation and Research (CDER), said in a press release. “The FDA is committed to ensuring the American consumer has access to the most effective and safe therapies, including over-the-counter products like sunscreens.” Why FDA approval of bemotrizinol is significant Bemotrizinol is the first new active ingredient added to an over-the-counter (OTC) m

healthline.com

FDA Clears AI Tool to Spot Cardiovascular Disease Risk Ahead of Symptoms

A first-of-its-kind AI tool was cleared by the FDA to detect underlying structural heart disease before symptoms present. ljubaphoto/Getty Images The FDA cleared the first artificial intelligence tool to detect hidden structural heart disease during routine ECGs. EchoNext is a heart screening designed to detect underlying disease before symptoms present. The new tool is credited with spotting severe, undiagnosed heart failure in a 45-year-old man who ultimately received a successful heart transplant. Cardiovascular disease, the leading cause of death globally, has not yet had an early-detection test — until now. On June 22, the Food and Drug Administration (FDA) cleared a new tool to detect heart disease early. EchoNext is an artificial intelligence tool that reads a standard electrocardiogram (ECG) and flags those at high risk for structural heart disease, according to its maker, Pathway Labs. The company said that it’s the first AI tool approved by the FDA to detect this kind of hidden heart disease from an electrocardiogram, and that the clearance covers six indications. In June, Nature Medicine published the first peer-reviewed case in which EchoNext flagged severe, undiagnosed heart failure in a 45-year-old patient who ultimately received a heart transplant. Larger trials are underway, and Pathway Labs has raised $8.5 million to expand into more health systems, according to the company. EchoNext was built by researchers at NewYork-Presbyterian and Columbia University, led by Pathway Labs’ founder and CEO Pierre Elias, MD, an assistant professor of Medicine in the Department of Biomedical Informatics at Columbia University Data Science Institute. “We don’t have a screening test for the most common cause of death in the world, which is most forms of cardiovascular disease,” Elias said in a video released by NewYork-Presbyterian. “So we asked ourselves, could we take a cheap and ubiquitous test, and using AI, turn it into a screening test? And it turns out, we can

healthline.com

EMT Simone Kelly On the Opioid Overdose That Went Viral: ‘Don't Be a Bystander’

Simone Kelly went viral after reviving a man with Narcan at the Knicks parade. Here, she shares her passion for treating addiction. Simone Kelly, 24, a pre-med student and volunteer EMT, is pursuing her calling in emergency psychiatry and addiction. Courtesy of Simone Kelly Simone Kelly was off-duty during the New York Knicks celebration parade in Lower Manhattan when she climbed a subway platform at the World Trade Center to save a man’s life with Narcan on June 18. Kelly, a 24-year-old volunteer EMT with the South Orange Rescue Squad in New Jersey, and a pre-med student at Drew University, captured the attention and hearts of millions. Her act of heroism demonstrated that anyone can step in during an opioid emergency. Kelly was joined by another anonymous healthcare worker and several others. “It was a bit chaotic — people in the crowd were just throwing things they thought might help,” Kelly told Healthline. “A bottle of water came up, and we poured that on him, hoping he’s just overheating from hyperthermia. Then someone tossed up Narcan, and I was glad there was someone else in the crowd who was gauging what this could be. At that point, there is no harm in administering Narcan, so that is what we did,” she said. Kelly typically carries intranasal naloxone with her everywhere, but that day, she left it at home to lighten her load at the parade. “It’s on my keys. It’s very bulky, and my keys have broken numerous times, not necessarily from the Narcan. But that day I did not have it,” Kelly said. “I remember standing in my kitchen with my keys in one hand and the Narcan in the other, like I don’t have pockets, I can’t bring a bag. I’ve always brought it, but never had to use it on the street.” Kelly’s passion for helping people with addiction is evident. She’s studying neuroscience with a minor in psychology and chemistry, and says she’s found some of her favorite people riding the ambulance as an EMT. Her calling, she says, is in emergency psychiatry and addicti

healthline.com

Get Health & Fitness delivered to your inbox

Owl Post delivers a personalized health & fitness digest every morning, curated by AI, written in your voice.

Get your free digest
More in Lifestyle
Explore other beats
From the Owl Post blog